vimarsana.com

Page 73 - Bascom Palmer Eye Institute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medical Technology Company Heru, Inc\ Completes FDA Registration Following a $2\ 7M Seed Round

Medical Technology Company Heru, Inc. Completes FDA Registration Following a $2.7M Seed Round By Staff 3 months ago Heru, Inc. comes out of stealth mode to announce the development of a novel artificial intelligence (AI) driven vision diagnostic and augmentation platform Heru’s technology registered with the FDA for its ground-breaking AI-powered visual field test using augmented reality Originating as a spinout from Bascom Palmer Eye Institute, ranked number one in ophthalmology and recognized as a global leader in vision research, medical education, and patient care Industry veteran John Trefethen joins Heru’s leadership team as Chief Marketing Officer Funding round led by Maurice R. Ferre, MD, Fred H. Moll, MD and a syndicate of seasoned technology veterans

Roche s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness – IT Business Net

Roche s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness

F. Hoffmann-La Roche Ltd Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies More than half of participants in the faricimab personalised dosing arms had extended time between treatments to 16 weeks at year one – the first time this level of durability has been achieved in a phase III diabetic macular edema study

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.